Russell Investments Group Ltd. Sells 10,580 Shares of Moderna, Inc. $MRNA

Russell Investments Group Ltd. decreased its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 6.2% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 159,663 shares of the company’s stock after selling 10,580 shares during the period. Russell Investments Group Ltd.’s holdings in Moderna were worth $4,557,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Theleme Partners LLP boosted its position in shares of Moderna by 1.0% during the 4th quarter. Theleme Partners LLP now owns 7,306,861 shares of the company’s stock valued at $303,819,000 after purchasing an additional 72,028 shares in the last quarter. Invesco Ltd. boosted its holdings in Moderna by 17.5% in the first quarter. Invesco Ltd. now owns 5,883,624 shares of the company’s stock worth $166,801,000 after acquiring an additional 877,162 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Moderna by 8.7% in the fourth quarter. The Manufacturers Life Insurance Company now owns 3,341,924 shares of the company’s stock worth $138,957,000 after acquiring an additional 267,990 shares in the last quarter. Northern Trust Corp boosted its holdings in Moderna by 13.6% in the fourth quarter. Northern Trust Corp now owns 2,959,054 shares of the company’s stock worth $123,037,000 after acquiring an additional 354,871 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Moderna by 12.2% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,629,865 shares of the company’s stock worth $74,557,000 after acquiring an additional 285,662 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the company. Citigroup assumed coverage on Moderna in a report on Friday, August 1st. They issued a “neutral” rating and a $40.00 price target on the stock. Cowen assumed coverage on Moderna in a report on Sunday, July 13th. They issued a “hold” rating on the stock. Leerink Partners cut their price target on Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a report on Friday. Evercore ISI set a $32.00 price objective on Moderna in a research note on Friday, August 1st. Finally, UBS Group lowered their price objective on Moderna from $78.00 to $70.00 and set a “buy” rating for the company in a research note on Friday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, sixteen have given a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Moderna presently has a consensus rating of “Hold” and an average target price of $42.88.

Moderna Price Performance

Moderna stock opened at $27.12 on Friday. Moderna, Inc. has a one year low of $23.15 and a one year high of $84.28. The business has a fifty day moving average price of $29.18 and a 200-day moving average price of $29.12. The firm has a market capitalization of $10.55 billion, a P/E ratio of -3.60 and a beta of 1.83.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, August 1st. The company reported ($2.13) EPS for the quarter, topping analysts’ consensus estimates of ($2.99) by $0.86. Moderna had a negative return on equity of 25.96% and a negative net margin of 94.31%.The firm had revenue of $142.00 million during the quarter, compared to analyst estimates of $116.26 million. During the same period last year, the company earned ($3.33) earnings per share. The business’s revenue for the quarter was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. Sell-side analysts expect that Moderna, Inc. will post -9.61 earnings per share for the current fiscal year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.